Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients by Udumyan, Ruzan et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=igas20
Scandinavian Journal of Gastroenterology
ISSN: 0036-5521 (Print) 1502-7708 (Online) Journal homepage: https://www.tandfonline.com/loi/igas20
Beta-adrenergic receptor blockers and liver cancer
mortality in a national cohort of hepatocellular
carcinoma patients
Ruzan Udumyan, Scott Montgomery, Ann-Sofi Duberg, Fang Fang, Unnur
Valdimarsdottir, Anders Ekbom, Karin E. Smedby & Katja Fall
To cite this article: Ruzan Udumyan, Scott Montgomery, Ann-Sofi Duberg, Fang Fang, Unnur
Valdimarsdottir, Anders Ekbom, Karin E. Smedby & Katja Fall (2020) Beta-adrenergic receptor
blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients,
Scandinavian Journal of Gastroenterology, 55:5, 597-605, DOI: 10.1080/00365521.2020.1762919
To link to this article:  https://doi.org/10.1080/00365521.2020.1762919
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 15 May 2020. Submit your article to this journal 
Article views: 607 View related articles 
View Crossmark data Citing articles: 1 View citing articles 
ORIGINAL ARTICLE
Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort
of hepatocellular carcinoma patients
Ruzan Udumyana, Scott Montgomerya,b,c, Ann-Sofi Dubergd, Fang Fange, Unnur Valdimarsdottire,f,g,
Anders Ekbomb, Karin E. Smedbyb,h and Katja Falla,e
aClinical Epidemiology and Biostatistics, School of Medical Sciences, €Orebro University, €Orebro, Sweden; bDepartment of Medicine Solna,
Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden; cDepartment of Epidemiology and Public Health, University
College London, London, UK; dDepartment of Infectious Diseases, School of Medical Sciences, €Orebro University, €Orebro, Sweden;
eDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; fCenter of Public Health Sciences,
University of Iceland, Reykjavik, Iceland; gDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA; hHematology
Clinic, Karolinska University Hospital, Stockholm, Sweden
ABSTRACT
Background: b-adrenergic signaling has been implicated in the pathology of hepatocellular carcinoma
(HCC), but the evidence from clinical studies is limited. In this national population-based cohort study,
we investigated the possible association of b-adrenergic receptor blockers and cancer-specific mortal-
ity among patients with primary HCC diagnosed in Sweden between 2006 and 2014.
Methods: Patients were identified from the Swedish Cancer Register (n¼ 2104) and followed until 31
December 2015. We used Cox regression to evaluate the association of b-blockers dispensed within
90days prior to cancer diagnosis, ascertained from the national Prescribed Drug Register, with liver
cancer mortality identified from the Cause of Death Register, while controlling for socio-demographic
factors, tumor characteristics, comorbidity, other medications and treatment procedures.
Results: Over a median follow-up of 9.9months, 1601 patients died (of whom 1309 from liver cancer).
Compared with non-use, b-blocker use at cancer diagnosis [n¼ 714 (predominantly prevalent use,
93%)] was associated with lower liver cancer mortality [0.82 (0.72–0.94); p ¼ .005]. Statistically signifi-
cant associations were observed for non-selective [0.71 (0.55–0.91); p ¼ .006], b1-receptor selective
[0.86 [0.75–1.00); p ¼ .049] and lipophilic [0.78 (0.67–0.90); p ¼ .001] b-blockers. No association was
observed for hydrophilic b-blockers [1.01 (0.80–1.28); p ¼ .906] or other antihypertensive medications.
Further analysis suggested that the observed lower liver cancer mortality rate was limited to patients
with localized disease at diagnosis [0.82 (0.67–1.01); p ¼ .062].
Conclusion: b-blocker use was associated with lower liver cancer mortality rate in this national cohort
of patients with HCC. A higher-magnitude inverse association was observed in relation to non-selective
b-blocker use.
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Liver cancer is one of the leading causes of cancer-related
mortality worldwide [1]. Despite improving survival trends
[2], the prognosis of liver cancer is poor with worldwide 5-
year net survival estimates ranging from 5 to 30% [2].
A growing body of evidence suggests a role of b-adrener-
gic signaling in tumor biology, and links b-adrenergic-recep-
tor blockers with reduced cancer progression, especially in
early-stage disease [3], via inhibition of various cancer-related
cellular and molecular processes involved in sympathetic ner-
vous system (SNS) activation [4]. However, associations with
mortality vary by tumor site [5,6] and subtype [7,8].
The predominant adrenoreceptors expressed in the
human liver are of the a1- and b2-subtypes [9,10]. b2-adre-
noreceptors have been shown to mediate noradrenaline/
adrenaline-induced cell invasion and anoikis inhibition in
hepatocellular carcinoma (HCC) [11], the most common type
of primary liver cancer, and b2-adrenergic receptor signaling
has been linked to sustained HCC cell proliferation and sur-
vival [12]. A higher density of b2-adrenoreceptors has further
been detected in HCC tissue than in the nonadjacent non-
tumor liver tissue [13,14]. The b2-adrenoreceptor upregula-
tion has in turn been associated with clinico-pathological fac-
tors including large tumor size, vascular invasion, poor
differentiation, and poor prognosis [15]. Further, the most
frequently investigated b-blocker, propranolol, has been
shown to inhibit proliferation, promote apoptosis, induce S-
phase arrest [16], and reduce invasion and migration [17] in
liver cancer cells. A meta-analysis of randomized trials on
non-selective b-blockers for prevention of variceal bleeding
in patients with liver cirrhosis has linked non-selective
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b-blockers with reduced risk of HCC but not HCC mortality
[18]. However, the meta-analysis was limited by a small num-
ber of patients and events, mainly because the majority of
eligible trials did not register HCC incidence or HCC mortality
[18]. The evidence from studies designed to study the associ-
ation of b-blocker use with liver cancer survival is still scarce.
In a small (n¼ 36) retrospective study of adults with non-
metastatic HCC, b-blocker use has been associated with
improved overall survival [19]. In a population-based study
using the National Health Insurance Research Database of
Taiwan, propranolol was associated with improved overall
survival in unresectable/metastatic HCC [20].
In this large population-based cohort of patients with pri-
mary HCC, we therefore tested the hypothesis that b-blocker
use at cancer diagnosis may reduce liver cancer mortality rate.
Patients and methods
Study population and data sources
We used prospectively collected data available through
national Swedish registers to conduct this retrospective
cohort study. The unique personal identification number
assigned to all Swedish residents was used to perform indi-
vidual record linkage.
From the Swedish Cancer Register [21], we identified
patients (aged 18 years or older) diagnosed with first primary
liver cancer between 1 January 2006, and 31 December
2014, using the International Classification of Diseases (ICD)
7th revision code 155.0, and obtained information on tumor
stage and histology, year of diagnosis, and age at diagnosis.
Prescriptions of b-blockers, as well as other relevant medica-
tions dispensed during the 90-day period before liver cancer
diagnosis were identified from the Prescribed Drug Register [22]
using the Anatomic Therapeutic Chemical (ATC) classification
system. The number of distinct medication classes (medications
with the same initial five characters of the ATC classification)
was used to derive a medication-based comorbidity score to
account for overall disease burden [23,24]. Post-diagnostic col-
lection of a prescription for sorafenib, a kinase inhibitor used in
advanced-stage liver cancer, was also identified.
The Patient Register [25] provided data on specific comor-
bidity, liver resection, liver transplantation and loco-regional
therapies such as ablation and transarterial chemoembolization
(TACE) (Supplementary Table S1). The Total Population Register
provided migration data, while the LISA (Swedish acronym for
Longitudinal Database of Education, Income and Occupation)
[26] was used to ascertain the level of attained education, mari-
tal status and region of residence. The Cause of Death Register
[27] provided information on the underlying cause of death.
We excluded patients with liver cancer other than HCC
identified through the ICD-O-3 morphological code 81703
(Supplementary Figure S1).
b-Blocker exposure assessment
Patients were classified as exposed at the time of cancer
diagnosis if they had collected b-blockers from the pharmacy
any time during the 90 days preceding their cancer diagno-
sis, as prescriptions normally cover a period of 30 to 90 days
(maximum 1 year) in Sweden. b-blocker exposure was further
defined by receptor selectivity [nonselective (ATC codes:
C07AA and C07AG), selective (C07AB and C07FB02)],
and solubility (lipophilic, hydrophilic). Patients using both
selective and non-selective b-blockers were placed in the
non-selective subgroup, while users of both lipophilic and
hydrophilic types were included in the lipophilic subgroup.
Where possible, associations with individual b-blockers were
investigated.
b-blocker use was also classified as incident or prevalent
in a sensitivity analysis performed in 1965 patients diagnosed
on or after 1 October 2006, where use was defined as inci-
dent if patients collected their b-blockers from the pharmacy
within 90 days before cancer diagnosis date, but had no
recorded collection in the previous year.
Outcome assessment
Cancer-specific mortality (CSM) was identified from the
Causes of Death Register using ICD-10 code C22 capturing
cancer of the liver including intrahepatic cholangiocarci-
noma. Patients were followed from the date of cancer diag-
nosis until date of emigration, death, or 31 December 2015,
whichever came first.
Statistical analysis
Patient characteristics were tabulated by b-blocker use and
compared using the v2, ANOVA or median tests as appropri-
ate. The observed 6-month, 1-year, and 5-year overall survival
proportions were estimated using the actuarial method.
Flexible parametric survival analysis (baseline hazards were
modeled using splines with five degrees of freedom) [28]
was applied to estimate age-adjusted median survival and
liver cancer survival curves by b-blocker use. The multivari-
able fractional polynomials method [29] assessed the func-
tional form of continuous variables in the log-hazard
function. Cox regression models with time since diagnosis in
months as the underlying time scale were fitted to estimate
hazard ratios (HR) and 95% confidence intervals (CI) for the
b-blocker-CSM association. Test and plots of Schoenfeld
residuals evaluated the proportional hazards assumption,
which was satisfied for b-blockers.
Multivariable Cox regression models included age at can-
cer diagnosis, the medication-based comorbidity score, and
year of diagnosis modeled as linear measures; sex; attained
education [categories by duration: compulsory (up to
9 years), secondary (10–12 years), and postsecondary (more
than 12 years); marital status [categories: unmarried, married/
cohabiting, divorced/separated, or widowed]; region of resi-
dence; tumor–node–metastasis (TNM) stage [classified into
stages 1–4B (Supplementary Table S2)]; specific comorbid
diseases at liver cancer diagnosis [portal vein thrombosis,
diabetes, gastro-esophageal varices with and without bleed-
ing, viral hepatitis C and other types, diseases of liver under
ICD-10: K70-K77 capturing fibrosis/cirrhosis of the liver and
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other conditions] and specific medications [loop diuretics,
other antihypertensive medications, NSAIDs, aspirin and sta-
tins]. To identify presence of liver decompensation not iden-
tifiable through ICD codes in the data, we included use of
spironolactone and lactulose as indicators of cirrhotic ascites
and hepatic encephalopathy, respectively. A further adjusted
model (referred to as fully adjusted) included some other
indicators of liver function such as alcohol abuse-related
morbidity at diagnosis (more relevant in the Nordic countries
[30], as well as ablation, TACE, liver resection, liver transplant-
ation and sorafenib use. Ablation, TACE, liver resection, liver
transplantation, sorafenib use as well as portal vein throm-
bosis were modeled as time-varying covariates in the fully
adjusted model using time dependent Cox regression.
Multiplicative interaction terms were added to the fully
adjusted model to test whether associations differ by sex. In
a sensitivity analysis, we further adjusted for cardiovascular
diseases. Besides analyses in all HCC patients, analyses strati-
fied by known distant metastases at diagnosis (M stage at
diagnosis recorded as M0 or M1) were conducted.
Since patients with cirrhosis who have developed hepa-
torenal syndrome have been recommended to discontinue
or avoid b-blocker use [31], we performed a sensitivity ana-
lysis where patients with likely hepatorenal morbidity [identi-
fied through ICD codes for moderate-to-severe renal disease
and diseases under ICD-10 K76 code, which captures hepa-
torenal syndrome (K76.7)] were excluded. As it has been sug-
gested that non-selective b-blockers may be associated with
reduced survival in patients with hepatic decompensation/
refractory ascites [31], we performed an exploratory analysis
among patients likely to have decompensated liver disease.
This subgroup of patients was identified based on diagnoses
of hepatic failure (ICD-10: K72) or bleeding varices, or dis-
pensed prescriptions of lactulose or spironolactone. In
another sensitivity analysis among 1479 patients diagnosed
on or after 1 July 2006, we compared with non-use the use
of selective b-blockers and other antihypertensive medica-
tions dispensed for no other indication but hypertension (as
specified in the Prescribed Drug Register). Prior prescriptions
dispensed during 1 year before cancer diagnosis also had to
be for no other indication but hypertension.
All analyses were performed using Stata version 14/SE for
Windows (StataCorp) software. The study was approved by
an ethical review board in Uppsala (DNR: 2012-361).
Results
Study population and overall survival estimates
The analytic cohort included 2104 patients with primary
HCC. The median age at diagnosis was 68 years (range:
30–94 years). The cancer diagnosis was based on histopath-
ology (73.4%); X-ray, scintigraphy, ultrasound, magnetic res-
onance imaging, computed tomography, or equivalent
(3.0%); cytology (6.3%); or other laboratory tests (17.2%).
About half (51.4%) of the patients had no known distant
metastases at diagnosis. Patients with pre-existing liver mor-
bidity (n¼ 984) were more likely to be diagnosed at
early stages.
Over a total observation period of about 3316 person-
years, 1601 (76.1%) patients died, another 7 (0.3%) emi-
grated, and 496 (23.6%) were followed to the end of the
study. The causes of death were liver cancer (n¼ 1309), other
tumors (n¼ 84), cardiovascular disease (n¼ 55), or other
causes (n¼ 153) including chronic viral hepatitis (n¼ 38) and
diseases of liver (n¼ 46)]. The median survival
was 9.9months.
The estimated 6-month, 1-year, and 5-year overall survival
proportions were 59, 46, and 19%, respectively. The corre-
sponding estimates were 59, 45, 19% for non-users; 55, 42,
13% for selective b-blocker users and 74, 62, 35% for non-
selective b-blocker users.
b-Blocker use
Overall, 714 (34%) patients used b-blockers at the time of
liver cancer diagnosis. Most commonly prescribed b-blockers
belonged to the b1-cardio-selective type (68.1%), consisting
predominantly of lipophilic metoprolol, while non-selective
b-blockers comprised 33.9% and consisted mainly of lipo-
philic propranolol (Supplementary Table S3). Only 15 (2.1%)
users received agents belonging to different b-blocker
classes (for example, both selective and non-selective).
b-Blockers with partial agonist activity were very rare.
The majority (about 93% of users) had received b-blockers
also before the 90-day exposure window used by the study.
Only a few (38 users of non-selective and 24 users of select-
ive types) met the incident user definition for a sensitivity
analysis performed in patients diagnosed on or after 1
October 2006.
In general, b-blocker users were more likely to be mar-
ried/cohabiting and had a higher comorbidity score.
Compared with users of selective b-blockers or non-users,
users of non-selective types tended to be younger and more
likely to be diagnosed with portal vein thrombosis, gastroe-
sophageal varices, viral hepatitis, and various liver diseases
[particularly, alcoholic liver disease (ICD-10: K70), hepatic fail-
ure (K72), fibrosis/cirrhosis of liver (K74), and other diseases
of liver (K76)] as well as to be diagnosed at early stages of
cancer (Table 1). Medications associated with cirrhotic ascites
and hepatic encephalopathy were also more common
among non-selective b-blocker users. Users of selective
b-blockers had fewer years of education and were more
likely to be diagnosed with diabetes, moderate-to-severe
renal disease and cardiovascular diseases other than varices
and portal vein thrombosis (for example, coronary artery dis-
ease, chronic heart failure and cerebrovascular disease).
Other antihypertensive medications were also more common
among users of selective b-blockers.
b-Blocker use and liver cancer specific mortality
The CSM rates (per 100 person-months) were lower among
b-blocker users than non-users [2.85 (2.59–3.14) and 3.54
(3.32–3.78), respectively] with a corresponding statistically
significant HR of 0.85 (0.76–0.96; p ¼ .007). Further analysis
suggested that the lower CSM rates among users were
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b–blocker (N¼ 472) No b–blocker (N¼ 1390)
paN Col% N Col % N Col%
Age at diagnosis, years (mean, SD) 63.3 9.2 72.3 8.8 66.6 11.4 <.001b
Male 197 81.4 346 73.3 1041 74.9 .050
Attained education .023
Compulsory 91 37.6 233 49.4 619 44.5
Secondary 120 49.6 178 37.7 570 41.0
Post-secondary 31 12.8 61 12.9 201 14.5
Marital status at diagnosis <.001
Unmarried 39 16.1 54 11.4 244 17.6
Married/cohabiting 125 51.7 253 53.6 655 47.1
Divorced/separated 61 25.2 83 17.6 337 24.2
Widowed 17 7.0 82 17.4 154 11.1
TNM stage <.001
Stage 1 55 22.7 61 12.9 190 13.7
Stage 2 51 21.1 56 11.9 160 11.5
Stage 3A 13 5.4 47 10.0 149 10.7
Stage 3B 2 0.8 10 2.1 20 1.4
Stage 4A 10 4.1 23 4.9 55 4.0
Stage 4B 18 7.4 79 16.7 215 15.5
Recorded incompletelyd 57 23.6 82 17.4 351 25.3
Missinge 36 14.9 114 24.2 250 18.0
No distant metastases (M stage¼M0) 146 60.3 224 47.5 711 51.2 .002
Comorbidity score (median, IQR)f 7 4–10 8 5-11 4 2-7 <.001c
Comorbidity before HCC diagnosis
Varices without bleeding 176 72.7 16 3.4 138 9.9 <.001
Varices with bleeding 63 26.0 5 1.1 43 3.1 <.001
Viral hepatitis C 99 40.9 48 10.2 362 26.0 <.001
Viral hepatitis B, D 43 17.8 16 3.4 145 10.4 <.001
Various diseases of liverg 203 83.9 94 19.9 466 33.5 <.001
Portal vein thrombosis 13 5.4 8 1.7 19 1.4 <.001
Diabetes 99 40.9 242 51.3 429 30.9 <.001
Cardiovascular diseaseh 136 56.2 409 86.7 662 47.6 <.001
Moderate-severe renal disease 13 5.4 48 10.2 46 3.3 <.001
Other medicationsi
Other anti-hypertensive medicationsj 61 25.2 334 70.8 402 28.9 <.001
Lactulosek 53 21.9 19 4.0 90 6.5 <.001
Spironolactonel 94 38.8 47 10.0 109 7.8 <.001
Loop diureticsm 88 36.4 140 29.7 176 12.7 <.001
NSAIDs 14 5.8 46 9.7 159 11.4 0.025
Aspirin 25 10.3 201 42.6 177 12.7 <.001
Statins 27 11.2 174 36.9 145 10.4 <.001
Patients were considered exposed to b-blocker use at cancer diagnosis if they collected at least one prescription during the 90-day period before cancer diagno-
sis, and unexposed otherwise. Patients using both selective and non-selective b-blockers (n¼ 14) are in the non-selective subgroup. TNM recording in the
Cancer Register was introduced in 2004 and has improved over time. Diabetes and chronic lower respiratory diseases were defined using ICD codes from the
Patient Register and medications (ATC: A10 and R03, respectively) from the Prescribed Drug Register; other comorbidities were defined using ICD codes in the
Patient Register. Moderate-severe renal disease includes end stage renal disease.
ATC: Anatomic Therapeutic Chemical classification system; ICD: International Classification of Diseases; IQR: interquartile range; SD: standard deviation.
ap Values are from a v2 test.
bRobust one-way ANOVA.
cMedian test.
dEither T, N or M stage was not specified.
eCaptured patients with either all T, N, M stages missing or recorded as TxNxMx.
fNumber of distinct medication classes (medications with the same initial five characters of ATC classification) within 90 days before cancer diagnosis were used
to derive a comorbidity score.
gIncludes alcoholic liver disease (ICD-10: K70), toxic liver disease (K71), hepatic failure (K72), chronic hepatitis (K73), fibrosis and cirrhosis of liver (K74), other
inflammatory liver diseases (K75), other diseases of liver (K76).
hOther than varices and portal vein thrombosis.
iMedications (yes/no variables) are dispensed within 90 days before cancer diagnosis and are not mutually exclusive.
jInclude angiotensin-converting enzyme inhibitors (ATC: C09: A, BA, BB), angiotensin receptor blockers (C09: C, DA, DB), calcium channel blockers (C08) and thia-
zide diuretics (C03A).
kLactulose (ATC: A06AD11) is used for hepatic encephalopathy and as a laxative.
lSpironolactone (ATC: C03DA01) is the drug of choice for cirrhotic ascites if there is no renal failure. Other indications include hypokalemia, idiopathic edema,
and nephrotic syndrome.
mLoop diuretics (ATC: C03CA): mainly (99%) furosemide (C03CA01), which complements the effect of spironolactone for edema caused by hepatic cirrhosis. Also
indicated for the diuretic treatment of chronic heart failure and acute pulmonary edema.
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driven by rates among users of non-selective [1.51
(1.25–1.83)] rather than selective [4.09 (3.66–4.57)] b-blockers.
In age-adjusted analyses, any b-blocker use was associated
with a 19% lower CSM (Figure 1, Table 2). The estimates
remained largely unchanged and statistically significant after
further multivariable adjustments (Table 2). Additional adjust-
ment for cardiovascular diseases (main indications for b-blocker
use, particularly selective types) did not affect the results.
Figure 1. Age-adjusted liver cancer survival curves by b-blocker use among patients with primary hepatocellular carcinoma diagnosed in 2006 to 2014 in Sweden.
Survival curves were estimated using flexible parametric survival analysis. The adjusted curves show the survival we would expect to see in exposure groups if
each had the age distribution of the study population as a whole (to compare like with like). Values on the plot are age-adjusted median survival estimates by
b-blocker use.
Table 2. Cox proportional hazards regression analyses for the association between b-blocker use and liver cancer mortality in patients diagnosed with primary
hepatocellular carcinoma (N¼ 2104) in Sweden in 2006–2014.
b-blockersa No. of events HRb (95% CI) p HRc (95% CI) p HRd (95% CI) p
Any b-blocker 414 0.81 [0.72, 0.91] <.001 0.84 [0.73,0.95] .008 0.82 [0.72, 0.94] .005
Non-selectivee 106 0.58 [0.48, 0.72] <.001 0.74 [0.58, 0.95] .017 0.71 [0.55, 0.91] .006
b1-receptor selectivef 308 0.94 [0.82, 1.07] .362 0.87 [0.75, 1.00] .053 0.86 [0.75, 1.00] .049
Lipophilicg 327 0.76 [0.67, 0.86] <.001 0.80 [0.69, 0.92] .002 0.78 [0.67, 0.90] .001
Hydrophilich 87 1.09 [0.88, 1.37] .422 1.00 [0.80, 1.26] .974 1.01 [0.80, 1.28] .906
ATC: Anatomic therapeutic chemical classification system; CI: confidence interval; HR: hazard ratio; TNM: tumor–node–metastasis.
aExposed if collected at least one prescription during the 90-day period before liver cancer diagnosis, unexposed otherwise. Patients using both selective and
non-selective b-blockers (n¼ 14) are in the non-selective subgroup, and patients using both lipophilic and hydrophilic b-blockers (n¼ 2) are in the lipo-
philic subgroup.
bb-blocker use compared with non-use adjusting for age at diagnosis.
cb-blocker use compared with non-use adjusting for age at diagnosis, sex, TNM stage, diagnosis year, healthcare/residence region, attained education, marital
status, comorbidity score (number of distinct ATC classes prescribed during 90 days prior to diagnosis), diabetes, gastroesophageal varices with and without
bleeding, viral hepatitis C and other, various liver diseases, portal vein thrombosis, other anti-hypertensive medications, NSAIDs, aspirin, statin, loop diuretics,
lactulose, spironolactone.
dFurther adjusted for alcohol abuse related morbidity at diagnosis, as well as ablation, transarterial chemoembolization (TACE), liver transplantation, liver resec-
tion, and sorafenib use modeled as time-varying covariates. Portal vein thrombosis is also modeled as time-updated covariate in this model.
eIncludes pindolol, propranolol, sotalol, labetalol, carvedilol.
fIncludes metoprolol, atenolol, bisoprolol, metoprololþ felodipine.
gIncludes bisoprolol, carvedilol, labetalol, metoprolol, pindolol, propranolol, metoprololþ felodipine.
hIncludes: sotalol, atenolol.
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Analyses differentiating b-blockers by receptor selectivity
suggested higher-magnitude associations for non-selective
b-blockers, although the difference between the estimates
was not statistically significant (p ¼ .143) (Table 2). The haz-
ard ratio for the association between non-selective b-blocker
use and CSM was not significantly altered after adjustment
for diagnosis of gastroesophageal varices, the most common
indication for non-selective b-blocker treatment, although
some attenuation of the inverse association was observed.
Analyses by solubility further indicated lower CSM for
lipophilic but not hydrophilic b-blocker use (difference
between the estimates: p ¼ .036) (Table 2). There were no
notable differences between men and women.
Results for selected individual b-blockers were consistent
with results for b-blocker types evaluated in aggregate
(Table 3). Non-selective and highly lipophilic propranolol was
associated with a statistically significant 28% lower mortality
rate, and commonly prescribed b1-selective and highly lipo-
philic metoprolol was associated with a 19% lower mortality
rate. A higher magnitude association (48% lower mortality
rate) was observed for the less often prescribed carvedilol, a
moderately lipophilic and non-selective b-blocker with anti-
a1 adrenergic activity. Use of moderately lipophilic bisoprolol
or hydrophilic atenolol, both with higher (compared with
metoprolol) b1-selectivity, did not show associations
with CSM.
In our sensitivity analysis we observed similar magnitude
associations for incident and prevalent use of non-selective
b-blockers [0.71 (0.44–1.14) vs. 0.70 (0.53–0.93)] as well as for
incident and prevalent use of selective b-blockers [0.87
(0.52–1.46) vs. 0.83 (0.71–0.97)].
Stratified analyses suggested a lower CSM among patients
without known distant metastases at diagnosis [0.82
(0.67–1.01), p ¼ .062], whereas the magnitude of association
was close to null in patients with distant metastases [0.98
(0.71–1.36), p ¼ .910].
In exploratory analyses among 655 patients with indica-
tions of decompensated liver disease, non-selective b-block-
ers were still associated with lower CSM [0.73 (0.50–1.05),
p¼ 0.089)] although statistical significance was not achieved.
Further analysis suggested an inverse association for
propranolol [n¼ 155; HR: 0.67 (0.46, 0.98)] but not for the
rarely used carvedilol [n¼ 5; HR: 1.33 (0.39, 4.55)]. The magni-
tude of association was close to null for selective b-blockers
[0.98 (0.72–1.33)].
Non-selective b-blockers were associated with lower CSM
[0.68 (0.51–0.90), p ¼ .007] also in a sensitivity analysis
excluding 363 patients with hepatorenal morbidity. A lower
magnitude association was observed in relation to selective
types [0.85 (0.73–1.00), p ¼ .055].
In a sensitivity analysis excluding patients who used
b-blockers and/or other antihypertensive medications dis-
pensed for indications other than hypertension, selective
b-blockers were associated with lower CSM, while other anti-
hypertensive medications were not (Table 4).
Discussion
In this large population-based cohort of patients with pri-
mary HCC, b-blocker use at cancer diagnosis was associated
with lower liver cancer specific mortality. The reduced liver
cancer mortality rate was limited to patients without known
distant metastases at diagnosis. Higher-magnitude inverse
associations were suggested for non-selective than selective
b-blockers, and the association was apparent for lipophilic
but not hydrophilic b-blockers.
HCC typically arises in the background of cirrhosis and
only about 20% of HCCs have been reported to develop in
non-cirrhotic livers [32]. While tumor recurrence is the major
cause of death in non-cirrhotic HCC [32], patients with HCC
in cirrhotic liver often die from complications of liver cirrhosis
and portal hypertension rather than from clearly tumor-
related causes. Non-selective b-blockers are recommended
for patients with cirrhosis and esophageal varices to prevent
variceal hemorrhage [33,34]; and have been shown to lower
the risk of spontaneous bacterial peritonitis in patients with
cirrhosis and ascites [35] and risk of developing ascitic
decompensation, refractory ascites and hepatorenal syn-
drome in patients with compensated cirrhosis [36]. Improved
survival associated with non-selective b-blockers may thus be
partly explained by reduced risk of hepatic decompensation-
related mortality. Unlike non-selective b-blockers, selective
Table 3. Cox proportional hazards regression analyses for the association between selected b-blockers and liver cancer mortality in patients diagnosed with pri-
mary hepatocellular carcinoma (N¼ 2104) in Sweden in 2006–2014.
b-blockersa b-receptor selectivity ratio Solubility No. of events HRb (95% CI) p HRc (95% CI) p
Non-selective b2 vs. b1
Propranolol 8.3 Highly lipophilic 88 0.74 [0.56, 0.97] .032 0.72 [0.55, 0.95] .021
Carvedilol 4.5 Moderately lipophilic 12 0.63 [0.35, 1.13] .120 0.52 [0.29, 0.94] .031
Selective b1 vs. b2
Metoprolol 2.3 Highly lipophilic 177 0.84 [0.70, 1.00] .053 0.81 [0.68, 0.97] .021
Atenolol 4.7 Hydrophilic 84 1.00 [0.79, 1.27] .973 1.01 [0.80, 1.28] .928
Bisoprolol 13.5 Moderately lipophilic 49 0.82 [0.61, 1.11] .195 0.90 [0.67, 1.22] .513
Note: Selectivity ratio means, e.g., that the affinity of bisoprolol is 13.5-fold more at the b1- than b2-receptor, while the affinity of propranolol is 8.3-fold more
at the b2- than b1-receptor. Carvedilol is a non-selective b-blocker that blocks b1 and b2 adrenergic receptors as well as a1 adrenergic receptors.
ATC: Anatomic therapeutic chemical classification system; CI: confidence interval; HR: hazard ratio.
aExposed if collected at least one prescription during the 90-day period before liver cancer diagnosis, unexposed otherwise.
bb-blocker use compared with non-use adjusting for age at diagnosis, sex, TNM stage, diagnosis year, healthcare/residence region, attained education, marital
status, comorbidity score (number of distinct ATC classes prescribed during 90 days prior to diagnosis), diabetes, gastroesophageal varices with and without
bleeding, viral hepatitis C and other, various liver diseases, portal vein thrombosis, other anti-hypertensive medications, NSAIDs, aspirin, statin, loop diuretics,
lactulose, spironolactone.
cFurther adjusted for alcohol abuse related morbidity at diagnosis, as well as ablation, transarterial chemoembolization (TACE), liver transplantation, liver resec-
tion, and sorafenib use modeled as time-varying covariates. Portal vein thrombosis is also modeled as time-updated covariate in this model.
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b-blockers are more likely prescribed to patients with com-
pensated liver who thus have a better liver function related
prognosis irrespective of b-blocker use.
Increased surveillance of patients with cirrhosis leading to
earlier cancer detection [37] may offer another potential
explanation. This is less likely among patients with non-cir-
rhotic HCC as they are often diagnosed at an advanced stage
due to lack of surveillance [32].
A growing body of evidence has suggested a role of
b-adrenergic signaling in the pathobiology of various tumor
types [4], including liver cancer [11,12,15–17,19,38], and the
observed lower CSM rates among b-blocker users could also
be related to reduced cancer progression linked to inhibited
b-adrenergic signaling. The observed inverse association
between CSM and use of selective b-blockers but not other
antihypertensive medications dispensed for hypertension
may add some additional suggestive evidence for the role of
b-adrenergic signaling in HCC pathology.
A lower mortality rate among patients without distant
metastases is consistent with the concept of greater influ-
ence of biobehavioral factors in early stage cancer when the
metastatic capacity is physiologically modifiable [3], although
some benefit even for late-stage disease may exist due to
treatment-sensitizing effects of b-blockers [39].
It has been suggested that the b2-adrenoreceptor is the
adrenoreceptor most involved in cancer related processes
[40], including for liver-cancer [11,12,15,38]; and that pro-
pranolol, shown to have antiproliferative, antimigratory, and
cytotoxic properties [16,17], may be more cytotoxic for liver
cancer cells than atenolol [17]. This could potentially partially
explain the higher-magnitude associations with non-selective
b-blockers (comprised mainly of propranolol in this cohort).
However, b1- and b2-receptors are in general very similar,
and the majority of b-blockers used in clinical practice
(including metoprolol and atenolol) show little selectivity for
the b1- over the b2-adrenoreceptor [41]. Our results further
suggested an association of lipophilic b-blockers with
reduced CSM, while no association was observed for hydro-
philic b-blockers. As lipophilic agents have greater
penetrance of the blood-brain barrier, this finding may sug-
gest that some of the hypothesized anti-tumor effects of
b-blockers may be mediated through central b-adrenergic
signaling [4]. Carvedilol, a non-selective b-blocker with anti-
a1 adrenergic activity, which demonstrated higher magni-
tude associations in our study overall, has been studied as a
promising b-blocker in liver pathology [31,34], but perhaps
not among patients with severe or refractory ascites [31].
Strengths of this study include use of high-quality pro-
spectively collected data from national registers in the set-
ting of a tax-supported universal health care system,
minimizing the risk of selection bias, and substantially reduc-
ing the likelihood of the findings being confounded by soci-
oeconomic characteristics.
Defining exposure to medications through dispensed pre-
scriptions prevents problems such as recall bias or failure to
fill prescribed medication (a key component of non-adher-
ence). However, exposure misclassification is still possible,
and a prescription filled does not guarantee that the dis-
pensed medication has been used. Although the information
on medication compliance is unavailable, the requirement
for patients to pay a component of the dispensed price
should increase the probability of actual use. Our definition
of exposure does not account for potential changes in use
during follow-up, but resembles the intention-to-treat ana-
lysis in randomized studies and eliminates the possibility of
immortal time bias. Besides studying b-blockers in aggregate,
we studied some individual b-blockers with varying b-recep-
tor ligand selectivity and lipophilicity/hydrophilicity.
However, these analyses are limited by low prevalence of
some b-blockers. For example, the low prevalence of hydro-
philic sotalol and lack of lipophilic timolol, both with higher
b2-selectivity compared to propranolol [41], limits the possi-
bility to make inferences regarding relative importance of
b2-selectivity level and solubility of non-selective types. As
the medication data are only available since the start of the
register in July 2005, we were unable to evaluate the role of
duration of b-blocker use [42], the significance of which is
largely unknown [43]. Since comparison of prevalent users
Table 4. Cox proportional hazards regression analyses for the association between antihypertensive medications and liver cancer
mortality in patients diagnosed with primary hepatocellular carcinoma in Sweden between 1 July 2006 and 31 December
2014 (N¼ 1479).
Antihypertensive medications
dispensed for hypertensiona No. of events HRb (95% CI) p
Selective b-blockers 178 0.82 [0.68, 0.98] .030
ACEi 155 0.96 [0.79, 1.17] .703
ARBs 122 1.16 [0.94, 1.43] .162
CCB 160 0.95 [0.79, 1.15] .589
Thiazide diuretics 36 0.91 [0.65, 1.30] .615
ACEi: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; ATC: Anatomic therapeutic chemical classifica-
tion system; CCB: calcium channel blockers; CI: confidence interval; HR: hazard ratio.
aExposed if collected at least one prescription during the 90-day period before liver cancer diagnosis dispensed for no other indica-
tion but hypertension. Prior prescriptions dispensed during 1 year before cancer diagnosis also had to be for no other indication
but hypertension.
bAntihypertensive medication use compared with non-use adjusting for age at diagnosis, sex, TNM stage, diagnosis year, health-
care/residence region, attained education, marital status, comorbidity score (number of distinct ATC classes prescribed during
90 days prior to diagnosis), diabetes, gastroesophageal varices with and without bleeding, viral hepatitis C and other, various liver
diseases, NSAIDs, aspirin, statin, loop diuretics, lactulose, spironolactone, alcohol abuse related morbidity, as well as ablation, trans-
arterial chemoembolization (TACE), liver transplantation, liver resection, sorafenib use, and portal vein thrombosis modeled as time-
updated covariates.
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with non-users could be subject to selection bias [44], we
examined associations for incident and prevalent b-blocker
use compared with non-use. This analysis, although limited
by a small number of incident users, did not reveal any clear
differences between estimates for incident and preva-
lent use.
Due to the observational nature of the study, the possibil-
ity of residual confounding cannot be excluded, and con-
founding by indication [45] or by liver functional status is
possible. Although the national register data allowed us to
account for a number of important potential confounding
and prognostic factors, the data was limited by the absence
of stage information according to Barcelona-Liver Cancer
(BCLC) staging system, one of the most widely used classifi-
cations for HCC in cirrhotic liver that accounts not only for
tumor extent but also for other determinants of prognosis
such as liver function and performance status [46]. The
nature of the registry data limited our ability to accurately
identify all patients with and without underlying cirrhosis
and to adjust for severity of cirrhosis through Child-Pugh
score or other specific measures of the underlying liver func-
tion [46]. Nevertheless, the inability to efficiently adjust for
performance status and cirrhosis severity could explain the
observed inverse associations if patients with poor perform-
ance status and more advanced liver impairment, who tend
to have worse prognosis, were less likely to take b-blockers,
for example, patients with cirrhosis who have developed
hepatorenal syndrome [31,47]. However, excluding patients
with hepatorenal morbidity did not affect the results. As
b-blocker users tended to be older and with higher disease
burden, the observed inverse association with CSM is less
likely to be explained by selective avoidance of prescribing
b-blockers to frail patients. Furthermore, patients on non-
selective b-blockers generally have more advanced portal
hypertension with large gastroesophageal varices [47].
In conclusion, b-adrenergic receptor blockers, particularly
non-selective types, are associated with lower liver cancer
mortality in patients with primary HCC. Various potential
mechanisms could explain the observed inverse association,
including an influence on hepatic decompensation-related
mortality as well as early detection of cancer due to active
surveillance (particularly among patients with HCC in cir-
rhotic liver). Reduced cancer progression due to b-adrenergic
signaling inhibition could be another potential explanation.
Further clinicopathological investigations are necessary to
disentangle potential mechanisms. Thus, the role of b-block-
ers, particularly propranolol, in HCC progression could be an
area for further investigation, but the findings from pre-
clinical and observational studies need to be verified by
prospective clinical trials.
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